[PI3K-AKT-mTOR pathway inhibitors].
Molecular targeted agents have enlarged the armamentarium of anti-cancer therapies. Along with the success of some anti-growth factor receptors, signal transduction inhibitors represent a promising anti-cancer strategy. The PI3K-AKT-mTOR pathway is a key pathway frequently altered in cancer cells. This manuscript provides an overview of the PI3K-AKT-mTOR pathway and its targeting in human malignancies. A focus is delivered for mTOR inhibitors.
Cortot
Alexis
A
Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulin, 94805 Villejuif.
Armand
Jean-Pierre
JP
Soria
Jean-Charles
JC
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011494:Protein Kinases / Q000502:physiology*; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases; C546842:MTOR protein, human